A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
This study tests an investigational medicine called safusidenib for adults with a specific type of brain tumor called a glioma that has a certain genetic change known as an IDH1 mutation. Researchers want to see how safe the medicine is and how well it works to help patients.
You may be able to join if you are 18 or older, have a confirmed Grade 2 or Grade 3 glioma with an IDH1 mutation, and your tumor has returned or grown after previous treatments. There are also specific rules about how recently you had surgery, radiation, or other cancer drugs.
Depending on which part of the study you join, you will receive either the study medicine, safusidenib, or a placebo, which looks like the medicine but contains no active drug. Your health and the effects of the treatment will be closely monitored by the study team throughout the process.
The study is currently recruiting participants at locations in states like Alabama and Arizona in the United States. Your care team can help you find the closest participating medical center.
- 1Evaluates an investigational targeted medicine called safusidenib
- 2Focuses on brain tumors with a specific IDH1 genetic mutation
- 3Currently actively recruiting participants at multiple locations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.